Danaher Corporation Stock Price, News & Analysis

Danaher Corporation (NYSE: DHR) has announced its Board of Directors approved a regular quarterly cash dividend of $0.32 per share of common stock. The dividend will be paid on October 31, 2025 to shareholders of record as of September 26, 2025.

Danaher (NYSE: DHR) has appointed Jonathan Leiken as Senior Vice President and General Counsel, effective August 25, 2025. Leiken, who brings nearly three decades of legal and leadership experience, will report to CEO Rainer Blair and join the Danaher Leadership Team.

Leiken succeeds Brian Ellis, who will retire after nearly 10 years as General Counsel. Ellis will remain with Danaher through February 2026 to support the transition. Prior to joining Danaher, Leiken served as Executive VP and Chief Legal Officer at Dollar Tree and Diebold Nixdorf, and has experience as a federal prosecutor and law firm partner.

Danaher (NYSE: DHR) announced that Matthew Gugino will succeed Matthew McGrew as Chief Financial Officer, effective February 28th, 2026. Gugino, currently Group CFO of Life Sciences Innovations Group and VP of Financial Planning & Analysis, brings extensive experience in Investor Relations, FP&A, and M&A.

McGrew, who has served as CFO since 2019, will transition to an Executive VP role as he approaches retirement after 20+ years with the company. During his CFO tenure, Danaher nearly doubled both revenue and market capitalization while improving growth and margin profiles. McGrew played key roles in the Cytiva acquisition and the launches of Envista and Veralto.

Danaher (NYSE: DHR) reported strong second quarter 2025 results, with revenues increasing 3.5% year-over-year to $5.9 billion and non-GAAP core revenue growth of 1.5%. The company posted net earnings of $555 million, or $0.77 per diluted share, while non-GAAP adjusted diluted earnings reached $1.80 per share.

Operating cash flow stood at $1.3 billion, with non-GAAP free cash flow of $1.1 billion. For full year 2025, Danaher maintains its core revenue growth forecast of approximately 3% and has raised its adjusted EPS guidance to $7.70-$7.80 from the previous $7.60-$7.75. The company expects low-single-digit core revenue growth for Q3 2025.

Danaher (NYSE:DHR) has appointed Martin Stumpe as Chief Technology and AI Officer, effective October 1, 2025. Reporting directly to CEO Rainer Blair, Dr. Stumpe will lead the company's digital transformation initiatives and AI integration across its global businesses.

Dr. Stumpe, who joined Danaher in 2024 as Chief Data and AI Officer, brings significant expertise from his previous roles at Tempus, where he led AI initiatives in precision medicine, and Google, where he founded the Cancer Pathology project. His appointment aims to accelerate scientific discovery, operational efficiency, and clinical impact in life sciences and diagnostics.

Danaher (NYSE:DHR) has appointed Greg Milosevich as Executive Vice President of its Life Sciences business, effective July 1, 2025. Milosevich, who has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021, will become an executive officer while continuing to report to CEO Rainer Blair.

Milosevich joined Danaher in 2010 through the Molecular Devices acquisition and has overseen multiple companies including Beckman Coulter Life Sciences, Sciex, Leica Microsystems, Molecular Devices, Phenomenex, Abcam, IDBS and Genedata. He holds a physics degree from the University of Puget Sound.

Danaher Corporation (NYSE: DHR) has scheduled its second quarter 2025 earnings conference call for Tuesday, July 22, 2025, at 8:00 a.m. ET. The hour-long call will cover the company's financial performance and future outlook. Investors can access the webcast and slide presentation through Danaher's website under the "Investors" section. U.S. participants can dial 800-245-3047, while international callers should use +1 203-518-9765 (Conference ID: DHRQ225). The earnings press release, webcast slides, Form 10-Q, and other financial materials will be available on the website at 6:00 a.m. ET on the call date. A replay will be accessible until August 5, 2025.

SCIEX, a Danaher Corporation subsidiary, has formed a reseller agreement with Evosep Biosystems to co-sell SCIEX mass spectrometry systems with the new Evosep Eno for standardized high-throughput proteomics. The collaboration aims to provide pharmaceutical and biotech researchers with improved proteomics workflows. Research shows the Evosep Eno delivers over 5x increase in peptide precursor identifications and 3x increase in protein group identifications when paired with the ZenoTOF 8600 system. The agreement covers 19 countries across North America and Europe, with SCIEX managing customer relationships while Evosep provides UHPLC service support. This partnership enhances accessibility to advanced proteomics technology and standardized solutions.

SCIEX, a Danaher Corporation subsidiary, has launched the ZenoTOF 8600 system at ASMS 2025, establishing new benchmarks in accurate mass quantitation. The system features significant improvements including 10x better sensitivity compared to the ZenoTOF 7600+ system, enhanced ion transmission through OptiFlow Pro source and ion guides, Mass Guard technology for contamination protection, and ZT Scan DIA 2.0 for expanded mass range coverage. The launch includes SCIEX OS software version 4.0 and new collaborations with MS-Dial for metabolomics analysis and PEAKS Studio 13 for proteomics workflows, enabling more comprehensive and efficient data analysis capabilities.